Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 65% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.

Open platform

Novo's Wegovy Reduced Liver Fat To Normal Levels In 88.5% Of Obese Adults With Excess Liver Fat At Week 72

By Reuters News11:19 (UTC), 1 October 2026 Updated

Oct 1 (Reuters) - Novo Nordisk A/S NOVOb.CO:

NOVO NORDISK: WEGOVY REDUCED LIVER FAT TO NORMAL LEVELS IN 88.5% OF OBESE ADULTS WITH EXCESS LIVER FAT AT WEEK 72
NOVO NORDISK: ANALYSIS SHOWED EVEN PARTICIPANTS WITH LOW BASELINE LIVER FAT SAW IMPROVEMENTS IN LIVER HEALTH WITH WEGOVY TREATMENT
NOVO NORDISK: ANALYSIS SHOWED THAT 23 OF 26 PARTICIPANTS WITH LIVER FAT ABOVE 5% REACHED BELOW 5% THRESHOLD BY WEEK 72
NOVO NORDISK: MEASURES SHOWED LIVER FAT DECLINED FROM 8.8% TO 3.1% AT WEEK 72 WITH WEGOVY IN STEP UP TRIAL

Further company coverage: [NOVOb.CO]

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.